Diabetes affects nearly 24 million people in the United States. The most widespread form is type 2 diabetes, accounting for about 90 to 95 percent of all diagnosed cases of diabetes, according to the American Diabetes Association (ADA). The research team at New York Hospital Queens is offering the community a chance to participate in a new type 2 diabetes study. The study, called TINSAL-T2D (Targeting Inflammation using Salsalate in Type 2 Diabetes), looks at the safety and effectiveness of an investigational medication (similar to aspirin) in the treatment of type 2 diabetes. The study medication has been approved by the U.S. Food and Drug Administration to treat arthritis, but it has not yet been approved for diabetes.
Cardium Provides Update On Phase 2b Excellarate Clinical Study And Plans For Additional Tissue Repair Applications
Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) provided an update on the completion of their MATRIX Phase 2b clinical study and announced plans to provide detailed safety and efficacy data for their Excellarate(TM) product candidate around the end of September. The MATRIX trial, a prospective, randomized, double-blind, placebo-controlled study, has enrolled 124 diabetic patients with non-healing, lower extremity neuropathic ulcers. The companies also reported that results from the MATRIX clinical study are expected to be used to support additional studies and applications of Tissue Repair's Gene Activated Matrix(TM) or GAM(TM) technology for ulcers and other potential applications, including not only the repair of soft tissue injuries such as diabetic or pressure ulcers, but hard tissue injuries such as those affecting bone.
A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss. The results of the trial in 21 people investigating the effects of pioglitazone (also known as Actos ) were published last month in the Journal of Neuroimmunology. Although the results of the trial showed some evidence of less damage in the brains of people with MS, there were too few people in the study to determine whether this effect was real. Dr. Susan Kohlhaas, Research Communications Officer at the MS Society said, "These results suggest that pioglitazone may have some benefit in combination with beta-interferon for people with relapsing remitting MS, but this trial is not large enough to determine exactly what that benefit will be.
Elron Group Company Medingo Receives Formal FDA Clearance To Market Its Insulin Micropump In The United States
Elron Electronic Industries Ltd. (NASDAQ & TASE: ELRN) announced, that further to it previous announcement on July 28, 2009, Medingo Ltd., a group company held 92% by Elron and its subsidiary, RDC - Rafael Development Corporation Ltd., has received formal clearance from the Food and Drug Administration ("FDA"), to market its Solo™ MicroPump Insulin Delivery System in the United States. Medingo intends to introduce the Solo™ MicroPump at the American Association of Diabetes Educators Meeting which will take place in August 2009 in Atlanta, U.S.A. "We are very excited to have received FDA clearance for Medingo's innovative, miniature, tube-free, insulin delivery system, " commented Arie Mientkavich, Chairman of Medingo and Elron.
Pediatric researchers have found that a gene previously shown to be involved in the development of type 2 diabetes also predisposes children to having a lower birth weight. The finding sheds light on a possible genetic influence on how prenatal events may set the stage for developing diabetes in later childhood or adulthood. Researchers from The Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine published the study July 10 in the online version of the journal Diabetes. "It's a bit unusual to find a gene linked to both prenatal events and to a disease that occurs later in life, " said study leader Struan F.
International Diabetes Federation Launch Landmark Action Plan To Tackle Rising Diabetes Epidemic In Africa
The International Diabetes Federation African Region (IDF Africa) launched a critical action plan today to address the escalating threat that diabetes poses to the region. The plan identifies three key areas of action: government, primary healthcare and the community, defining a clear step-based strategy for tackling diabetes and implementing the UN Resolution on diabetes in Africa. IDF Africa is now calling for immediate adoption and implementation of the action plan, to tackle a disease which if not addressed soon has potential to threaten the viability of many African economies.1 At the beginning of the 20th century, type 1 and type 2 diabetes was rare in Africa, but with the rapid urbanization and change in social lifestyle in the 21st century, there has been a rise in the disease and its complications.